SGLT2 Inhibitors in Diabetic CKD: Metabolic Wins, Neutral Surrogates
This meta-analysis quantifies short- to medium-term surrogate, metabolic, and safety effects of SGLT2 inhibitors specifically in diabetic CKD, reinforcing a favorable risk profile while cautioning about volume depletion.
📅 Journal publication: Oct 2, 2026·Last updated: Oct 5, 2026
SGLT2 inhibitors offer metabolic benefits but risk volume depletion in diabetic CKD.
Chronic kidney disease (CKD) in diabetes is linked with high cardiovascular risks. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer potential renoprotective and metabolic benefits. SGLT2 inhibitors reduced glycated hemoglobin by 0.40%, body weight by 1.36 kg, and systolic blood pressure by 2.98 mm Hg without significant changes in estimated glomerular filtration rate (eGFR) or urinary albumin-to-creatinine ratio (UACR). They increased the risk of volume depletion-related events. SGLT2 inhibitors offer metabolic benefits in diabetic CKD, but clinical use should consider potential volume depletion risks. Long-term studies indicate cardiorenal protection. SGLT2 inhibitors provide glycemic and hemodynamic benefits in diabetic CKD, with manageable safety concerns.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Shi X, Fu K, Hu M, Li R, Li H, Xu S
Citation:Shi X, Fu K, Hu M, et al. Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis. Medicine. 2026;105(40):e50957. doi:10.1097/MD.0000000000050957